Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630994 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00630994: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00630994 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00630994, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying the side effects and how well low-dose decitabine works in treating patients with symptomatic myelofibrosis.
Interventions
- DRUG Dacogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630994
The ClinicalTrials.gov registry entry for NCT00630994 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dacogen is the first listed.
NCT00630994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00630994 about?
NCT00630994 is a clinical study titled "Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis". RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying the side effects and how well low-dose decitabine works in treating patients ...
What is the current status of trial NCT00630994?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-03. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00630994?
The interventions under investigation include: Dacogen (DRUG).
Who is sponsoring clinical trial NCT00630994?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.